



NDA 021821/S-049

SUPPLEMENT APPROVAL

PF Prism CV
c/o Pfizer Inc.
Attention: Nestor Duci, MBA
Senior Manager, Pfizer Global Regulatory Affairs
445 Eastern Point Road,
Groton, CT 06340

Dear Mr. Duci:

Please refer to your supplemental new drug application (sNDA) dated January 13, 2020, received January 13, 2020, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tygacil (tigecycline) for Injection.

This Prior Approval supplemental new drug application provides for proposed safety related updates to the following sections of the US Prescribing Information:

Section 2 DOSAGE AND ADMINISTRATION and **Section 5 WARNINGS AND PRECAUTIONS:** Recommendation for monitoring of blood coagulation parameters, including blood fibrinogen

Section 6 ADVERSE REACTIONS: Addition of “hypofibrinogenemia” as a postmarketing adverse reaction

In addition, **Section 7 DRUG INTERACTIONS**, was updated with the description of a drug interaction regarding concomitant use of Tygacil with calcineurin inhibitors.

Minor editorial revisions were made throughout the labeling.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (Prescribing Information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

If you have any questions, call Christopher L. Smith, PharmD, MPH, Regulatory Project Manager at (301) 796-4851.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Prescribing Information

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
06/23/2020 01:03:37 PM